Sclerosis, Systemic clinical trials at UC Health

• A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis

  open to eligible people ages 18 years and up

  This study is the extension of the double-blind study GLPG1690-CL-204 (NCT03798366). The main purpose of the study is to see how GLPG1690 is tolerated in participants with systemic sclerosis and whether there are any side effects in a long-term treatment period.

  at UCLA

Last updated: May 13, 2020